IRON
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Disc Medicine, Inc. (IRON) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+). The rating has held at C for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | C+ (2.5) | D+ (1.7) | D+ (1.6) | C+ (2.6) | C+ (2.6) | C (2.2) |
| 2026-11-05 | C+ (2.5) | D+ (1.7) | D+ (1.6) | C+ (2.7) | C+ (2.7) | C (2.2) |
| 2026-10-29 | C+ (2.5) | D+ (1.7) | D+ (1.5) | C+ (2.7) | C+ (2.7) | C (2.2) |
| 2026-10-22 | C+ (2.5) | D+ (1.6) | D+ (1.5) | C+ (2.5) | C+ (2.6) | C (2.2) |
| 2026-10-15 | C+ (2.5) | D+ (1.6) | D+ (1.5) | C (2.2) | C+ (2.6) | C- (2.1) |